Phase 1/2 Open-label, Multiple-dose, Dose-escalation Study to Evaluate the Safety andTolerability of IMO-8400 in Patients with Relapsed or Refractory Diffuse Large B-CellLymphoma and MyD88 L265P Mutation
A study for patients with Diffuse Large B-cell Lymphoma using study drug IMO-8400
Sponsor: Idera Pharmaceuticals
Enrolling: Male and Female Patients
Clinic Visits: 10
IRB Number: AAAO7060
U.S. Govt. ID: NCT02252146
Contact: Michelle Malanga: / mm4629@cumc.columbia.edu
Additional Study Information: The purpose of this study is to see if study drug IMO-8400 is safe and effective in the treatment of patientswith relapsed or refractory Diffuse Large B-Cell Lymphoma following conventional treatment.Examples of conventional treatment are radiotherapy, immunotherapy, chemotherapy, orradioimmunotherapy. Patients are scheduled to participate in this study from a total of eight (8) months from screening visit to the last follow-up visit. Over this period there are a total of 52 visits.
This study is closed
Investigator
Ahmed Sawas, MD
Do You Qualify?
Have you been diagnosie Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Michelle Malanga
mm4629@cumc.columbia.edu

This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE